EMEA-001679-PIP01-14

Key facts

Active substance
  • emtricitabine
  • rilpivirine
  • tenofovir alafenamide
Therapeutic area
Infectious diseases
Decision number
P/0356/2022
PIP number
EMEA-001679-PIP01-14
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral formulation
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Gilead Sciences International Ltd 
United Kingdom
Tel. +44 (0)1223 897300 
Fax +44 (0)1223 897284
E-mail: regulatory.pip@gilead.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating